Shire (SHPG) Affirms Positive PTAB Decision to Uphold LIALDA Patent

October 6, 2016 6:44 AM EDT
Get Alerts SHP Hot Sheet
Trade SHP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Shire plc (Nasdaq: SHPG) announced that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA (mesalamine) product.

The petition seeking to institute inter partes review (IPR) was filed with the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) in April of 2015 by the Coalition For Affordable Drugs (CFAD) II L.L.C. Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner.

Shire is pleased with the decision and will continue to vigorously defend its patents to protect the innovation and value Shire products bring to patients.

LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of UC. There have not been any approvals of generic versions of LIALDA.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Litigation

Related Entities

Definitive Agreement

Add Your Comment